Skip to content

Corporate
- Pitch
- Mission
- CSR
- Team
Technology
- Publications
Pipeline
Clinical trials
Newsroom
Partnerships

Home
Corporate
- Pitch
- Mission
- CSR
- Team
Technology
- Publications
Pipeline
Clinical trials
Newsroom
Partnerships
Contact

C

1 min read

[Newsletter-5] NEWS/INFOS

Author Bertrand Fabien
Published 31 mai 2020

May 29, 2020.

>> Official news bulletin for XAV19/Bulletin officiel du XAV19 <<

Download our newsletter (english version)
Télécharger notre newsletter (version française)

Related Posts

XENOTHERA presents XON11, a new hope for the treatment of pancreatic cancer

October, 2024. At the 36th ENA - EORTC - AACR symposium, Firas Bassissi, XENOTHERA CSO, presented highly promising results in pancreatic cancer.

XENOTHERA ANNOUNCES THE RECRUITMENT OF THE FIRST PATIENT OF THE PALT1 TRIAL IN PERIPHERAL T-CELL LYMPHOMA (PTCL) AND ITS ORPHAN DRUG STATUS (ODD) BY THE EMA

August 24. Treatment with its antibody directed against tumor lymphocytes offers new hope for patients with PTCL

XENOTHERA publishes the clinical efficacy of XAV-19, its anti-COVID antibody, in Frontiers in Immunology

June, 2024. During its participation in ASCO, XENOTHERA….

Corporate
Technology
Pipeline

Clinical trials
Newsroom
Partnerships

Contact
Legal notice

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@akkanto.fr